In summary, analysis of the infiltrate of the uninjected melanoma reveals that intra-tumoral TLR9 agonist therapy may mobilize CD8 T cells that traffic to the distal lesion and benefit from anti-CTLA-4 mediated Treg depletion or enhanced expansion relative to suppressive myeloid stroma mediated by anti-PD-1. The gene discussed is TLR9; the disease is melanoma.